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Dasatinib (BMS-354825, SPRYCEL, Bristol-Myers Squibb,
New York, NY, USA) is an ATP-competitive protein tyrosine
kinase inhibitor (TKI), which was originally identiﬁed as a potent
inhibitor of Src family kinases (including Src, Lck, Hck, Yes, Fgr,
Lyn and Fyn) and was subsequently found to have activity against
Abl, Kit, the macrophage colony stimulating factor receptor (Fms),
the platelet-derived growth factor (PDGF) receptor (PDGFR)-a
and -b and the Eph receptor family members EphB1, EphB2 and
EphB4.
1–3 Dasatinib is an effective therapy for chronic myeloid
leukaemia (CML) in patients who are resistant to front-line
imatinib mesylate therapy due to its increased afﬁnity for the CML
oncoprotein BCR-Abl and its insensitivity to mutations in the
BCR-Abl kinase domain. Furthermore, recent data suggest that
dasatinib may be more effective than imatinib as a front-line
therapy for chronic phase CML.
4
The success of TKIs for the treatment of CML has resulted in
the investigation of the use of these drugs in an increasing
number of paediatric haematological and solid tumours.
However, although TKI treatment is generally well tolerated,
there is emerging data to suggest that TKI therapy may result in
decreased growth in children. Three recently published case-
studies report decelerated growth in juvenile CML patients
undergoing imatinib therapy.
5–7 Additionally, a French phase IV
trial has recently reported decreased growth in a cohort of 22
children and adolescents (age: 10 months–17 years) receiving
imatinib therapy for chronic-phase CML.
8 Growth rates in this
group were signiﬁcantly lower following imatinib treatment,
with a signiﬁcant decrease in height z-score (median,  0.37;
range,  1.09 to þ0.14) after 12 months of treatment, compared
with baseline.
8 In keeping with this, we have previously
reported that imatinib treatment caused growth plate closure
in normal rats in vivo and inhibit chondrocyte proliferation and
activity in vitro,
9 providing a possible explanation for the
reduced longitudinal growth observed in juvenile patients
treated with imatinib.
In paediatric cases that are resistant or intolerant to imatinib
and where allogeneic transplants are not possible, dasatinib
is recommended as a second-line therapy. In light of this
increased investigation of the use of dasatinib in the treatment
of paediatric cancers, we investigated whether dasatinib, like
imatinib, affected the growth plate in vivo.
In this study, it was found that dasatinib treatment resulted in
a signiﬁcant decrease in cartilagenous growth plate thickness in
normal rats. Sprague–Dawley rats were treated with dasatinib
(5mg/kg) or vehicle (10% DMSO/90% PEG 300) by daily oral
gavage for up to 12 weeks and the proximal tibial growth plate
was examined by histology. In vehicle-treated controls, the
width of the cartilagenous growth plate at the proximal tibia
remained constant at all time-points examined (P¼0.070,
one-way ANOVA; Figure 1). In contrast, the mean growth plate
thickness decreased signiﬁcantly over time in dasatinib-treated
animals, with complete closure at the centre of the growth plate
in two of ﬁve animals after 12 weeks. The width of the growth
plate was signiﬁcantly lower in the dasatinib-treated group than
in vehicle-treated controls after 12 weeks of treatment (Po0.05;
Figure 1).
Postnatal longitudinal bone growth in the axial and appendi-
cular limb skeleton is controlled by the regulated proliferation
and activity of chondrocytes and osteoblasts within the
epiphyseal growth plate. This process of endochondral
ossiﬁcation involves the chondrocyte-mediated production of
a cartilagenous template, which is later mineralised and
remodelled to form mature lamellar bone. We postulate that
the accelerated growth-plate narrowing observed in dasatinib-
treated rats may be due, in part, to the inhibition of chondrocyte
proliferation and activity.
To determine whether dasatinib directly affects chondrocyte
proliferation and activity, the effects of dasatinib on the murine
pre-chondrocyte cell line ATDC5 were investigated in vitro.
ATDC5 cells were cultured for up to 6 days with dasatinib or
vehicle and the relative number of cells per well was
determined by WST-1 assay. In vehicle-treated cultures, cell
numbers increased fourfold during the 6 days of culture
(Figure 2a). Treatment of ATDC5 cells with dasatinib signiﬁ-
cantly inhibited cell proliferation at concentrations of 2.5nM
and higher after 2, 4 or 6 days, with an IC50 of 6.2nM on day 6.
The effects of dasatinib on chondrocyte activity were next
investigated using a GAG-synthesis assay. ATDC5 cultures were
treated with 10ng/ml rhTGF-b1, an inducer of chondrocyte
differentiation and activity (Figure 2b). Dasatinib treatment for
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Figure 1 The proximal tibial growth plate is thinned in dasatinib-
treated animals. Nine-month-old female Sprague–Dawley rats were
treated for 12 weeks with dasatinib (5mg/kg per day) or vehicle
(10% DMSO/90% PEG 300). Six animals per group were humanely
killed after 4, 8 and 12 weeks of treatment and right tibiae were
collected for histological analysis. Samples were embedded in parafﬁn
and 5-mm sections were stained with safranin O/fast green. Growth
plate thickness was measured at ﬁve equidistant points across the
centre of the growth plate. Box plots depict median, 25th and 75th
percentiles±range (n¼4–6).
nPo0.05 (Student’s t-tests).
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www.nature.com/bcj48h signiﬁcantly decreased TGF-b1-induced GAG synthesis at
40nM concentrations and higher, with a 40% reduction in GAG
synthesis at 40 and 80nM dasatinib, relative to vehicle controls
(Figure 2b). These data demonstrate that dasatinib inhibits
proliferation and extracellular matrix synthesis in cultures of
chondrocyte-like cells in vitro, suggesting that inhibition of
chondrocyte proliferation and activity may be responsible for
the decreased growth plate thickness observed in the dasatinib-
treated normal rats.
The dasatinib target PDGFR is an important regulator of
chondrocyte proliferation and activity. PDGF-BB is a known
mitogen for chondrocytes and has been reported to promote
chondrocyte activity in at least some cell types,
10,11 suggesting
that dasatinib treatment may have direct effects on chondrocyte
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Figure 2 Dasatinib inhibits cell proliferation and activity in ATDC5 cultures. (a) ATDC5 cells (1.56 10
4 cells per cm
2) were seeded in 96-well
plates in a-MEM with 10% fetal bovine serum, 2mML-glutamine, 1mM sodium pyruvate, 15mM HEPES, 50U/ml penicillin, 50mg/ml streptomycin
and 100mM ascorbate (c-a-MEM) and were cultured overnight to allow the cells to adhere. The cells were then treated with dasatinib or vehicle
(0.05% DMSO) for the indicated periods of time before the relative number of cells per well were determined by WST-1 assay. Graphs depict
mean±range of two representative experiments.
nPo0.05 relative to vehicle control at each time-point (one-way ANOVA with Dunnett’s post-
tests). (b) ATDC5 cells (1.56 10
5 cells per cm
2) were treated with rhTGF-b1 (10ng/ml) and the indicated doses of dasatinib or 0.05% DMSO
vehicle for 48h. GAG levels were then quantitated and normalised to DNA content to determine relative GAG production per cell. Graphs
depict mean±s.e.m. of triplicate wells of a representative experiment, normalised to the rhTGF-b1-treated vehicle control.
nPo0.05 relative to the
rhTGF-b1-treated vehicle control (one-way ANOVA with Dunnett’s post tests). (c) ATDC5 cells were cultured overnight at 1.56 10
5 cells per cm
2
in six-well plates in c-a-MEM. The cells were serum starved by overnight incubation in serum-free a-MEM. The cells were pre-treated with
dasatinib or 0.05% DMSO for 2h before stimulation with rhPDGF-BB (10ng/ml) for 5min. Cell lysates (30mg per lane) were resolved through a
10% sodium dodecyl sulphate-PAGE gel and the phosphorylated forms of Akt (p-Akt) and ERK1/2 (p-ERK1/2), as well as total HSP90, were
detected using speciﬁc antibodies. Images from a representative of two experiments are shown. (d) Graphs indicate the pixel intensity for
p-Akt and p-ERK1/2, relative to HSP90, normalised to vehicle controls. (e) ATDC5 cells were treated with 40nM dasatinib or vehicle (0.05%
DMSO) supplemented, where indicated, with 10ng/ml rhPDGF-BB. After 6 days, the relative number of cells per well was determined by WST-1
assay. Graphs depict mean±range of two representative experiments, normalised to vehicle control. (f) ATDC5 cells (cultured as in b) were then
treated with vehicle (V) or 40nM dasatinib (D) with or without 100ng/ml rhPDGF-BB. After 48h, GAG levels and DNA content were quantitated
and GAG production per cell was calculated. Graphs depict mean±s.e.m. of triplicate wells of a representative experiment, normalised to vehicle
controls.
nPo0.05, as indicated (Student’s t-tests).
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Blood Cancer Journalproliferation and activity through inhibition of PDGFR-b.
We examined whether inhibition of PDGFR-b contributed
to the inhibitory effects of dasatinib on ATDC5 proliferation
and GAG production. First, the effects of dasatinib on PDGFR
receptor signalling through Akt and ERK1/2 were examined
by western blot. Consistent with the known effects of dasatinib
on the PDGFR, dasatinib inhibited the rhPDGF-BB-induced
phosphorylation of Akt and ERK1/2 in a dose-dependent
manner, with 40nM dasatinib completely abrogating PDGFR
signalling (Figure 2c). Dasatinib inhibited PDGFR signalling
through Akt and ERK1/2 at IC50 of 13.0 and 16.0nM,
respectively (Figure 2d).
Consistent with the known effects of PDGF on chondrocyte
proliferation, treatment of ATDC5 with PDGF-BB for 6 days
increased the number of cells per well by 1.5-fold, compared
with vehicle-treated controls (Figure 2e). This increase in cell
proliferation was abrogated by dasatinib treatment (Figure 2e).
Additionally, treatment with rhPDGF-BB for 48h induced a
threefold increase in GAG production, on a per cell basis,
relative to untreated controls (Figure 2f). This stimulatory effect
of PDGF-BB was partially inhibited by co-treatment with 40nM
dasatinib, although levels did not reach those of unstimulated
dasatinib-treated cultures (Figure 2f).
In this study, dasatinib treatment partially reversed the
activating effects of PDGFR on the proliferation and GAG-
synthetic properties of the murine chondrocyte cell line ATDC5,
suggesting that inhibition of PDGFR signalling is likely to
contribute to the inhibitory effects of dasatinib on chondrocytes.
However, given the broad target speciﬁcities of dasatinib, other
tyrosine kinases may also have a role in the effects of dasatinib
on chondrogenesis. Inhibition of Src-family kinases may
contribute to the anti-proliferative effects of dasatinib on
chondrocytes, as inhibition of Src-family kinases with PP2 has
previously been found to inhibit chondrocyte proliferation
in vitro.
12–14 However, although Src
-/- mice have retarded long
bone growth, the growth plates of Src-deﬁcient mice are thicker
than normal
15 suggesting that inhibition of Src alone cannot
explain the growth plate thinning observed in this study.
In addition to inhibiting chondrocyte proliferation and
activity, dasatinib can affect osteoblast activity, inhibiting
stromal-cell proliferation while, under at least some conditions,
promoting osteoblast activity.
16–18 Growth plate thickness is
determined by rate of chondrocyte proliferation and hyper-
trophy and by the rate of replacement of the cartilagenous matrix
with mature bone. Therefore, the stimulation of osteoblast
activity by dasatinib may have additional effects on growth plate
thickness by accelerating growth plate mineralisation. However,
although published data suggest that dasatinib can increase
Sprague–Dawley osteoblast activity in vitro, we have previously
reported that treatment of normal Sprague–Dawley rats with
5mg/kg dasatinib had no effect on osteoblast activity.
16 These
ﬁndings suggest that the effects of dasatinib on the growth plate
in this study were independent of effects on osteoblast activity.
The putative effects of dasatinib on the growth plate may have
implications for the use of dasatinib in the paediatric setting.
Although these studies suggest that TKI therapy in pre-pubertal
individuals may retard growth, there are currently no reports
suggesting that dasatinib may also have effects on growth in
paediatric patients. Our results suggest that growth plate
changes should be investigated in paediatric patients who are
undergoing treatment with dasatinib. The relative beneﬁt of
using dasatinib as a front-line treatment for diseases affecting
children and adolescents may need to be re-evaluated,
taking into account the potential effects of dasatinib on the
growth plate.
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